Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC therapy for BPD in preterm babies
NCT02443961Phase 1Completed
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of expanded umbilical cord allogeneic fetal mesenchymal stem cells in bronchopulmonary dysplasia (BPD). Primary endpoint: Number of participants with adverse events at 24 months. Started Apr 2019; status: completed.
02
Drugs
expanded umbilical cord allogeneic fetal mesenchymal stem cells
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT02443961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443961.